drugset / Trial / NCT05875948
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
RandomizedSequentialSingle-blindTreatment
Summary
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
Timeline
- Start
- 2023-06-30
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | R2R01 | Unknown | 10 mg | — |
| Subject | Terlipressin | Peptide | 1 mg | Intravenous |
| Subject | Terlipressin | Peptide | 2 mg | Intravenous |